🔥Big News Press Release: Ph III ADRIATIC Trial meets OS & PFS Endpoints for Durva v Placebo in Limited Stage SCLC: - 730pts with LS-SCLC post cCRT - pts randomised to Durva +/- Treme post cCRT v pbo Can't wait to see the full data OncoAlert #LCSM astrazeneca.com/media-centre/p…

Amazing day with young people full of energy and hope University of Chicago Hematology/Oncology

In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy. Full trial results: nej.md/3VUzf3M

On 10 May at Istituto Tumori and online for the second edition of the "AI for Oncology" conference, we will explore how AI is transforming cancer. Under the auspices of ASCO, IASLC and AIOM. registrations to the event are still accepted @ aiforoncology.it ! #AI4Oncology

US FDA accepts for priority review BLA of zenocutuzumab (HER2/3 bispecific antibody) for patients with #NRG1 fusion NSCLC or pancreatic cancer. Fusions in NRG1 (neuregulin) are rare but important, can be missed by DNA NGS, best detected with RNA-seq. ir.merus.nl/news-releases/…

Ph III CM77T trial NEJM: Periop Nivo in Stage IIA-IIIB NSCLC: - neoadj nivo+chemo x 4 + 1yr adj nivo v neoadj chemo x 4 + 1yr adj pbo - EFS HR 0.58 (p<0.001), pCR 25.3% v 4.7% favoring nivo+chemo - g3+ TRAEs in 32.5% v 25.2% #TCascone OncoAlert #LCSM nejm.org/doi/full/10.10…

Should we infuse IO in the morning? Intriguing work just published: Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. We may need to analyze timing of IO infusion in phase III trials to guide us in our daily clinic. cell.com/cell/fulltext/…

Jonathan Spicer MD PhD McGillThoracic Thrilled and proud to be working with you Jonathan Spicer MD PhD, Lyndon Walsh McGillThoracic! Excitedly awaiting the results of other super interesting projects on prognostic and predictive factors in resectable NSCLC!!

Engaging discussions this morning on our IASLC Academy projects! Great to have Academy co-chair Christian Rolfo join us as our group mentor, providing tailored advice on our initiatives. #lcsm

#ARTICUNO study finally published! ESMO Open 📊 largest dataset of #NSCLC with uncommon #EGFR alterations treated with #osimertinib 🧬data on very rare alterations (snv, fusion, KDD), #intracranial activity, and #resistance mechanisms 🔎 #E709 mut->lack of benefit

Multidisciplinary consensus statement & practical recommendations on neoadjuvant & adjuvant therapy for early stage resectable NSCLC from IASLC now JTO & JTO CRR led by Drs. Jonathan Spicer MD PhD and Tina Cascone. jto.org/article/S1556-…

Stop pembro after 2 years? In 43,359 pts that received up-front pembrolizumab for an advanced NSCLC, continuation beyond 2 years was not associated with better OS than a fixed 2-year treatment, HR = 0.97 [0.75–1.26] p = 0.95. Adrien Rousseau sciencedirect.com/science/articl…

A friendly competition among the 2024 IASLC Academy class will culminate at #WCLC24. Participants Sally Lau, MD, and Maria Gemelli share thoughts about the experience in #ILCN: bit.ly/4dqszQO #LCSM

Just returned from WCLC and wanted to extend a huge thank you to the IASLC Academy for the incredible experience and opportunity! #WCLC2024 #IASLC

Wrapping up my ESMO experience and heading home. It’s been a whirlwind of emotions…..the first time for me as a speaker, exciting new data, and the pleasure of reconnecting with colleagues old and new. Thank you for the incredible moments! #ESMO2024

Cooperative Academic groups like #EORTC Lung Cancer Group are amazing!We have made our Spring meeting in Genova 🇮🇹with an outstanding group of Young Investigators 👏🏻.Lots ideas for future academic trials to ⬆️outcome of pts with 🫁 cancers. Working Together makes us stronger💪🏻

Exciting days at the EORTC Lung Cancer Group Spring Meeting! Innovative proposals, great teamwork, and strong support for young researchers. Happy to be part of this! #EORTC #LungCancer

📢 Now Online! Happy to share our latest meta-analysis on the role of ICIs in PD-L1 negative NSCLC. Grateful to all the co-authors 🔗 Full article here: doi.org/10.1016/j.lung… #NSCLC #immunotherapy #lungcancer

Dr. Tony Mok discusses #EGFR at #CIOT25. Emerging combinations like MARIPOSA and FLAURA2 improving outcomes - key is patient selection. Chemo-IO is out based on CM722 and KN789 but HARMONi could change things if OS superior. ADCs in 3L instead of 2L?

CIOT 2025 just concluded in Venice: top-notch content and inspiring discussions. Thank you all — see you next year in Palermo! #Oncology #LungCancer #CIOT